Introduction
============

Prostate cancer is the most common malignancy in men and a major cause of cancer-related deaths.[@b1-ott-10-3203] Since prostate-specific antigen (PSA)-based screening regime for prostate cancer remains controversial because of the high rate of overdiagnosis and overtreatment, a validated biomarker to complement PSA for screening and prognostic biomarkers with clinical utility remain an unmet need.[@b2-ott-10-3203]

In addition to androgens, estrogens also affect prostatic growth and carcinogenesis.[@b3-ott-10-3203] The cellular effects of estrogens are mediated by two estrogen receptors (ERs), ERα and ERβ. The human ERα encoding gene locates on chromosome 6q25.1 and consists of eight exons and seven introns.[@b4-ott-10-3203] Previous studies showed that the expression of ERα is gradually increased from prostate intraepithelial neoplasia, locally invasive cancers to metastatic lesions at both mRNA and protein levels.[@b5-ott-10-3203] Furthermore, in vivo studies using ERα knockout mice revealed that ERα is an important determinant of prostatic carcinogenesis.[@b3-ott-10-3203]

Although several single nucleotide polymorphisms (SNPs) have been identified in the ERα gene, only a few have been extensively studied in prostate cancer. Furthermore, substantial controversial conclusions have been drawn by these studies. To address these issues, we chose two common polymorphisms in the ERα gene, PvuII (rs2234693 T\>C) and XbaI (rs9340799 A\>G), and conducted a meta-analysis on case-control studies between prostate cancer patients and prostate cancer-free controls. The aim of this study was to investigate the potential role of ERα PvuII and XbaI polymorphisms in the prostate cancer risk stratification.

Methods
=======

The current meta-analysis was designed and reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement ([Table S1](https://pan.baidu.com/s/1cD2MUa)).[@b6-ott-10-3203]

Literature search
-----------------

Relevant papers published before October 1, 2016, were identified through a literature search in PubMed, Embase, and Cochrane databases using the following strategy: \[("gene mutation" OR "polymorphism") OR ("SNP") OR ("genetic variants")\] AND \[("prostate carcinoma") OR ("prostate neoplasms") OR ("prostate cancer")\] AND \[("estrogen receptor") OR ("estradiol receptor") OR ("ER") OR ("ESR")\]. References from eligible articles were also manually searched to identify other potential publications.

Study eligibility
-----------------

Studies were eligible for inclusion if, 1) studies focused on the association between ERα PvuII and *Xba*I polymorphisms and the prostate cancer risk; 2) they were case-control clinical studies on human subjects; 3) all diagnoses with prostate cancer were confirmed by pathological or histological examinations and controls were confirmed to be cancer free; 4) sufficient data were provided to estimate crude odds ratios (ORs) with 95% confidence intervals (CIs).

Two authors independently completed the screening process according to the Cochrane Collaboration guidelines.[@b7-ott-10-3203] The methodological quality of each retrieved study was assessed using the Strengthening the Reporting of Genetic Association Studies (STREGA) quality score system.[@b8-ott-10-3203] Forty-nine assessment items related to the quality appraisal were used in this score system with scores ranging from 0 to 49. Scores of 0--25, 26--37, and 38--49 were defined as low, moderate, and high quality, respectively ([Table S2](https://pan.baidu.com/s/1cD2MUa)).

Data extraction
---------------

Detailed data from each publication were independently extracted by two authors using a standardized data extraction sheet and were checked by a third author ([Table S3](https://pan.baidu.com/s/1cD2MUa)). The following information was extracted from each article: first author, year of publication, SNP ID and alternate name, ethnicity, country, language, study design, number of subjects, source of cases and controls, detecting sample, genotype method, allele and genotype frequencies, minor allele frequency (MAF), and evidence of Hardy--Weinberg equilibrium (HWE) in controls. Clinical parameters of prostate cancer patients were also collected, including tumor stage, serum PSA level at prostate cancer diagnosis, age at prostate cancer diagnosis, and smoking status. Risk of bias in each individual study was also evaluated.

Statistical analysis
--------------------

The association strength between both polymorphisms and the prostate cancer risk was measured by ORs with 95% CIs under five genetic models: allele model, dominant model, recessive model, homozygous model, and heterozygous model. The statistical significance of the pooled OR was examined by the *Z* test. Heterogeneity between studies was estimated using the *I*^2^ test. *I*^2^\<50% indicated that heterogeneity among studies was acceptable, and the fixed effects model (the Mantel--Haenszel method) was used. Otherwise, the random effects model (DerSimonian Laird method) was used. Subgroup analyses through ethnicity, country, source of cases and controls, genotype method, and whether HWE was in control or not were also conducted. We also stratified prostate cancer patients according to selected clinical param-eters. HWE was evaluated by the *χ*^2^ test in controls. Sensitivity analysis was performed by omitting each study in order to assess the stability of pooled results. Begger's funnel plots and Egger's linear regression test were used to evaluate publication bias. If significant publication bias existed, the trim and fill method was used to adjust pooled estimates.[@b9-ott-10-3203] All tests were two sided, and *P*\<0.05 was considered statistically significant. Data analysis was performed using the STATA software (version 12.0; Stata Corp, College Station, TX, USA).

Results
=======

Characteristics of included studies
-----------------------------------

According to the inclusion criteria, 18 case-control studies were included in the current meta-analysis.[@b10-ott-10-3203]--[@b27-ott-10-3203] The flow chart presenting the selection process is shown in [Figure 1](#f1-ott-10-3203){ref-type="fig"}. A total of 3,317 prostate cancer patients and 8,324 controls were included in the synthesis. Years of publications ranged from 2001 to 2015. Genotype frequencies among controls were consistent with the HWE test, except for three studies.[@b11-ott-10-3203],[@b24-ott-10-3203],[@b26-ott-10-3203] STREGA scores ranged from 29 to 36, which suggested that all of these studies were qualified to the quantitative synthesis. The characteristics and methodological quality of the included studies are summarized in [Tables 1](#t1-ott-10-3203){ref-type="table"} and [S4](https://pan.baidu.com/s/1cD2MUa).

ERα PvuII (rs2234693 T\>C) polymorphism and the prostate cancer risk
--------------------------------------------------------------------

Eighteen studies, comprising 3,317 cases and 8,324 controls, were involved in the synthesis. The results showed that PvuII polymorphism was related to an increased prostate cancer risk in overall populations under four genetic models (allele model OR: 1.16, 95% CI: 1.04--1.29, *P*\<0.01; dominant model OR: 1.24, 95% CI: 1.06--1.47, *P*=0.01; recessive model OR: 1.16, 95% CI: 1.04--1.30, *P*\<0.01; homozygous model OR: 1.37, 95% CI: 1.09--1.72, *P*\<0.01; [Tables 2](#t2-ott-10-3203){ref-type="table"} and [S5](https://pan.baidu.com/s/1cD2MUa)). To derive a more accurate estimation, subgroup analyses stratified by ethnicity were conducted. The results indicated that PvuII polymorphism was significantly correlated with a higher prostate cancer risk in Caucasians (allele model OR: 1.12, 95% CI: 1.03--1.21, *P*\<0.01; dominant model OR: 1.19, 95% CI: 1.05--1.35, *P*\<0.01; recessive model OR: 1.13, 95% CI: 1.03--1.29, *P*=0.04; homozygous model OR: 1.25, 95% CI: 1.06--1.46, *P*=0.01; [Tables 2](#t2-ott-10-3203){ref-type="table"} and [S5](https://pan.baidu.com/s/1cD2MUa)), but not in Asians. Furthermore, when grouped according to Gleason grades, PvuII polymorphism was found to be significantly correlated with high Gleason grade cancers (Gleason score ≥7) under the allele model (OR: 1.90, 95% CI: 1.44--2.50, *P*\<0.01, [Table 3](#t3-ott-10-3203){ref-type="table"}).

Sensitivity analysis suggested that individual studies did not affect pooled ORs ([Figure S1](https://pan.baidu.com/s/1cD2MUa)). Begger's funnel plot and Egger's linear regression test did not show any statistical evidence of publication bias ([Figure 2A](#f2-ott-10-3203){ref-type="fig"}). In addition, we excluded one study that deviated significantly from HWE, as the results showed that this non-HWE study had no effect on pooled ORs ([Table 2](#t2-ott-10-3203){ref-type="table"}).

ERα XbaI (rs9340799 A\>G) polymorphism and the prostate cancer risk
-------------------------------------------------------------------

The correlation between XbaI polymorphism and the prostate cancer risk was investigated in 13 studies with 1,946 cases and 2,744 controls. The results showed that XbaI polymorphism had a positive association with the risk of prostate cancer in overall populations under four genetic models (allele model OR: 1.23, 95% CI: 1.06--1.43, *P*\<0.01; dominant model OR: 1.38, 95% CI: 1.11--1.72, *P*\<0.01; recessive model OR: 1.24, 95% CI: 1.03--1.49, *P*=0.03; homozygous model OR: 1.44, 95% CI: 1.17--1.76, *P*\<0.01; [Tables 4](#t4-ott-10-3203){ref-type="table"} and [S6](https://pan.baidu.com/s/1cD2MUa)). Similarly, we performed a sub-group analyses based on ethnicity to derive a more accurate estimate, and the results showed that XbaI polymorphism was significantly correlated with an increased risk of prostate cancer in Caucasians (allele model OR: 1.31, 95% CI: 1.07--1.61, *P*\<0.01; dominant model OR: 1.43, 95% CI: 1.07--1.92, *P*=0.01; recessive model OR: 1.36, 95% CI: 1.09--1.69, *P*\<0.01; homozygous model OR: 1.48, 95% CI: 1.17--1.88, *P*\<0.01; [Tables 4](#t4-ott-10-3203){ref-type="table"} and [S6](https://pan.baidu.com/s/1cD2MUa)), but not in Asians.

Sensitivity analysis suggested that individual studies did not affect pooled ORs ([Figure S2](https://pan.baidu.com/s/1cD2MUa)). Begger's funnel plot and Egger's linear regression test did not show any statistical evidence of publication bias ([Figure 2B](#f2-ott-10-3203){ref-type="fig"}). Moreover, we excluded two studies that deviated significantly from the HWE test, and the results showed that these two non-HWE studies had no effect on pooled ORs ([Table 4](#t4-ott-10-3203){ref-type="table"}).

Discussion
==========

The role of PSA as a biomarker in prostate cancer remains unsatisfactory, leading to considerable overdiagnoses and overtreatment. This study on novel biomarkers in prostate cancer represents a long-standing hotspot in biomedical research.[@b28-ott-10-3203] Since ERα is an important determinant of prostatic carcinogenesis,[@b3-ott-10-3203] various studies have focused on SNPs in the ERα gene to determine their possible associations with the prostate cancer susceptibility. In the current study, we chose two common SNPs in the ERα gene, PvuII (rs2234693 T\>C) and XbaI (rs9340799 A\>G), and conducted a meta-analysis to evaluate their associations with prostate cancer susceptibility.

To our knowledge, the present work represents the largest meta-analysis performed to estimate the association of ERα SNPs with the risk of prostate cancer. The results showed that both PvuII and XbaI polymorphisms were correlated with an increased risk of prostate cancer in Caucasians, but not in Asians, and this disparity might be attributable to discrepancies in racial backgrounds and geography.[@b14-ott-10-3203],[@b29-ott-10-3203] Furthermore, there was a significant positive correlation of PvuII polymorphism and high Gleason grade cancers (Gleason score ≥7), which indicated its potential role in prostate cancer malignant transformation.

Both PvuII and XbaI polymorphisms lie in intron 1 of the ERα gene, which is part of the A/B domain, the trans-activating factor 1. This domain is an important site for stimulating transcription from certain estrogen-responsive promoters.[@b25-ott-10-3203] Among the possible explanations as to how these intronic polymorphisms affected prostate cancer risk are that, 1) both polymorphisms may be in linkage disequilibrium with other unknown variants in the gene, which may affect the gene expression or function;[@b24-ott-10-3203],[@b25-ott-10-3203],[@b30-ott-10-3203] 2) the alteration of another unidentified gene was adjacent to the ERα gene;[@b30-ott-10-3203] and 3) intronic changes may have an impact on the expression of receptors by influencing the transcription through alternative splicing of the mRNA transcript.[@b24-ott-10-3203] Although the susceptibility of Caucasians to prostate cancer is known to be much higher than that of Asians, the underlying mechanism remains unknown.[@b28-ott-10-3203] Our findings demonstrated the different roles of two ERα SNPs in prostate cancer risk estimation between Caucasians and Asians, indicating the probability of inherited susceptibility to prostate cancer arising from different genomic ERα SNPs, which may help elucidate the pathogenesis of prostate cancer.

Several limitations in this meta-analysis should be noted when interpreting our findings. First, the statistical power was still limited in the stratified analysis. Second, heterogeneity between studies was observed, although subgroup analyses were conducted to minimize the perturbation. Third, only published studies in English were included. Published studies in other languages, ongoing studies, and unpublished data were not obtained. Given these limitations, our conclusions should be interpreted cautiously.

Conclusion
==========

In summary, the current meta-analysis demonstrates the different roles of ERα PvuII and XbaI polymorphisms in prostate cancer risk stratification between Caucasians and Asians, indicating the probability of inherited susceptibility to prostate cancer arising from different genomic ERα SNPs, a finding that may help elucidate the pathogenesis of prostate cancer in Caucasians.
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![Flow of information through different phases of the present meta-analysis.\
**Abbreviation:** SNP, single nucleotide polymorphisms.](ott-10-3203Fig1){#f1-ott-10-3203}

![Begg's funnel plot for the publication bias test of the meta-analysis.\
**Notes:** Each point represents a separate study for the indicated association. Horizontal line represents size of effect. (**A**) ERα PvuII polymorphism (*t*=1.07, *P*=0.30) and (**B**) ERα XbaI polymorphism (*t*=0.66, *P*=0.52).\
**Abbreviations:** ERα, estrogen receptor α; OR, crude odds ratio; SE, standard error.](ott-10-3203Fig2){#f2-ott-10-3203}

###### 

Characteristics and methodological quality of included studies

  Study                                       Ethnicity   Country    SOC     Sample   Genotyping method   Participants   HWE     STREGA score   
  ------------------------------------------- ----------- ---------- ------- -------- ------------------- -------------- ------- -------------- ----
  **PvuII (rs2234693 T**\>**C) (n**=**18)**                                                                                                     
  Modugno et al,[@b10-ott-10-3203] 2001       Caucasian   America    PB      Blood    PCR                 81             233     Y              30
  Suzuki et al,[@b11-ott-10-3203] 2003        Asian       Japan      PB      Blood    PCR                 101            114     Y              31
  Tanaka et al,[@b12-ott-10-3203] 2003        Asian       Japan      PB      Tissue   PCR                 115            200     Y              29
  Fukatsu et al,[@b13-ott-10-3203] 2004       Asian       Japan      Mixed   Tissue   PCR                 116            238     Y              31
  Hernández et al,[@b14-ott-10-3203] 2006     Mixed       NA         Mixed   Blood    TaqMan              598            1,098   Y              31
  Low et al,[@b15-ott-10-3203] 2006           Caucasian   Britain    NA      Urine    TaqMan              75             158     Y              32
  Berndt et al,[@b16-ott-10-3203] 2007        Caucasian   NA         PB      Blood    TaqMan              470            603     Y              31
  Kjaergaard et al,[@b17-ott-10-3203] 2007    Caucasian   Denmark    HB      NA       PCR                 116            4,005   Y              36
  Onsory et al,[@b18-ott-10-3203] 2008        Asian       India      HB      Tissue   PCR                 100            100     Y              32
  Sobti et al,[@b19-ott-10-3203] 2008         Asian       India      HB      Blood    PCR                 157            170     Y              31
  Gupta et al,[@b20-ott-10-3203] 2010         Asian       India      HB      Blood    PCR                 157            170     Y              31
  Balistreri et al,[@b21-ott-10-3203] 2011    Caucasian   Sicily     NA      Tissue   TaqMan              50             47      Y              32
  Sissung et al,[@b22-ott-10-3203] 2011       Caucasian   America    PB      Blood    PCR                 128            126     Y              32
  Szendroi et al,[@b23-ott-10-3203] 2011      Caucasian   Hungary    PB      Blood    PCR                 194            103     Y              31
  Safarinejad et al,[@b24-ott-10-3203] 2012   Asian       Iran       NA      Blood    PCR                 162            324     Y              32
  Jurecekova et al,[@b25-ott-10-3203] 2013    Caucasian   Slovakia   PB      Blood    PCR                 311            256     Y              33
  Pazarbasi et al,[@b26-ott-10-3203] 2013     Asian       Turkey     PB      Blood    PCR                 34             27      N              32
  Lu et al,[@b27-ott-10-3203] 2015            Asian       Japan      PB      Blood    PCR                 352            352     Y              30
  **XbaI (rs9340799 A**\>**G) (n**=**11)**                                                                                                      
  Modugno et al,[@b10-ott-10-3203] 2001       Caucasian   America    PB      Blood    PCR                 82             237     Y              30
  Suzuki et al,[@b11-ott-10-3203] 2003        Asian       Japan      PB      Blood    PCR                 101            114     N              31
  Fukatsu et al,[@b13-ott-10-3203] 2004       Asian       Japan      Mixed   Tissue   PCR                 117            242     Y              31
  Hernández et al,[@b14-ott-10-3203] 2006     Mixed       NA         Mixed   Blood    TaqMan              598            1,098   Y              31
  Gupta et al,[@b20-ott-10-3203] 2010         Asian       India      HB      Blood    PCR                 157            170     Y              31
  Balistreri et al,[@b21-ott-10-3203] 2011    Caucasian   Sicily     NA      Tissue   TaqMan              50             47      Y              32
  Sissung et al,[@b22-ott-10-3203] 2011       Caucasian   America    PB      Blood    PCR                 129            127     Y              32
  Szendroi et al,[@b23-ott-10-3203] 2011      Caucasian   Hungary    PB      Blood    PCR                 205            101     Y              31
  Safarinejad et al,[@b24-ott-10-3203] 2012   Asian       Iran       NA      Blood    PCR                 162            324     N              32
  Jurecekova et al,[@b25-ott-10-3203] 2013    Caucasian   Slovak     PB      Blood    PCR                 311            256     Y              33
  Pazarbasi et al,[@b26-ott-10-3203] 2013     Asian       Turkish    PB      Blood    PCR                 34             28      Y              32

**Notes:** The study also used blood as testing sample. All cases came from hospital-based populations.

**Abbreviations:** SOC, source of controls; HWE, Hardy--Weinberg equilibrium (Y, HWE in controls; N, HWE out of controls); STREGA, Strengthening the Reporting of Genetic Association Studies; PB, population-based; PCR, polymerase chain reaction; NA, nonapplicable; HB, hospital-based.

###### 

Meta-analysis findings on the association between ERα PvuII (rs2234693 T\>C) polymorphism and prostate cancer risk

  Subgroup (size)                           *I*^2^                       OR (95% CI)   *P*-value
  ----------------------------------------- -------- ------------------- ------------- -----------
  **Allele model (C vs T)**                                                            
  Overall (n=20)                            57.1%    1.16 (1.04--1.29)   \<0.01        
  Caucasian (n=11)                          37.8%    1.12 (1.03--1.21)   \<0.01        
  Asian (n=8)                               74.6%    1.09 (0.85--1.39)   0.50          
  HWE in controls (n=19)                    56.7%    1.17 (1.05--1.30)   \<0.01        
  **Dominant model (TC** + **CC vs TT)**                                               
  Overall (n=20)                            55.2%    1.24 (1.06--1.46)   0.01          
  Caucasian (n=11)                          38.0%    1.19 (1.05--1.35)   \<0.01        
  Asian (n=8)                               73.3%    1.17 (0.79--1.73)   0.42          
  HWE in controls (n=19)                    57.1%    1.25 (1.06--1.48)   \<0.01        
  **Recessive model (CC vs TT** + **TC)**                                              
  Overall (n=20)                            38.1%    1.16 (1.04--1.30)   \<0.01        
  Caucasian (n=11)                          4.4%     1.13 (1.03--1.29)   0.04          
  Asian (n=8)                               62.5%    1.17 (0.81--1.70)   0.13          
  HWE in controls (n=19)                    33.1%    1.18 (1.05--1.31)   \<0.01        
  **Homozygous model (CC vs TT)**                                                      
  Overall (n=20)                            58.6%    1.37 (1.09--1.72)   \<0.01        
  Caucasian (n=11)                          29.5%    1.25 (1.06--1.46)   0.01          
  Asian (n=8)                               77.2%    1.31 (0.73--2.33)   0.35          
  HWE in controls (n=19)                    58.2%    1.41 (1.12--1.77)   \<0.01        
  **Heterozygous model (CC vs TC)**                                                    
  Overall (n=20)                            14.7%    1.11 (0.99--1.25)   0.07          
  Caucasian (n=11)                          0.0%     1.07 (0.93--1.23)   0.29          
  Asian (n=8)                               44.4%    1.16 (0.93--1.45)   0.17          
  HWE in controls (n=19)                    3.5%     1.12 (1.00--1.26)   0.05          

**Notes:** If *I*^2^\<50%, the fixed effects model was used. Otherwise, the random effects model was used.

**Abbreviations:** ERα, estrogen receptor α; OR, crude odds ratio; CI, confidence interval; HWE, Hardy--Weinberg equilibrium.

###### 

Subgroup analysis by Gleason score of the association between ERα *Pvu*II (rs2234693 T\>C) polymorphism and prostate cancer risk under the allele model (T vs C)

  Study (n=2)                                 Ethnicity   Gleason score         OR (95% CI)   Weight (%)                                               
  ------------------------------------------- ----------- --------------- ----- ------------- ------------ ----------------------- ------------------- -------
  Safarinejad et al,[@b24-ott-10-3203] 2012   Asian       150             58    90            58                                   1.67 (1.06--2.60)   41.09
  Jurecekova et al,[@b25-ott-10-3203] 2013    Caucasian   299             133   98            90           2.07 (1.45--2.93)       58.91               
  **Overall (*I*^2^**=**0.0%)**                                                                            **1.90 (1.44--2.50)**   **100**             

**Note:** *I*^2^\<50%, the fixed effects model was used.

**Abbreviations:** ERα, estrogen receptor α; OR, crude odds ratio; CI, confidence interval.

###### 

Meta-analysis findings on the association between ERα *Xba*I (rs9340799 A\>G) polymorphism and prostate cancer risk

  Subgroup (size)                           *I*^2^                       OR (95% CI)
  ----------------------------------------- -------- ------------------- -------------
  **Allele model (G vs A)**                                              
  Overall (n=13)                            56.5%    1.23 (1.06--1.43)   \<0.01
  Caucasian (n=7)                           64.5%    1.31 (1.07--1.61)   \<0.01
  Asian (n=5)                               54.5%    1.05 (0.80--1.37)   0.70
  HWE in controls (n=11)                    56.6%    1.25 (1.06--1.47)   \<0.01
  **Dominant model (AG** + **GG vs AA)**                                 
  Overall (n=13)                            59.2%    1.38 (1.11--1.72)   \<0.01
  Caucasian (n=7)                           65.5%    1.43 (1.07--1.92)   0.01
  Asian (n=5)                               58.1%    1.21 (0.82--1.79)   0.31
  HWE in controls (n=11)                    53.1%    1.37 (1.11--1.70)   \<0.01
  **Recessive model (GG vs AA** + **AG)**                                
  Overall (n=13)                            6.0%     1.24 (1.03--1.49)   0.03
  Caucasian (n=7)                           0.0%     1.36 (1.09--1.69)   \<0.01
  Asian (n=5)                               26.1%    1.00 (0.71--1.42)   0.79
  HWE in controls (n=11)                    10.5%    1.27 (1.04--1.55)   0.01
  **Homozygous model (GG vs AA)**                                        
  Overall (n=13)                            43.5%    1.44 (1.17--1.76)   \<0.01
  Caucasian (n=7)                           45.1%    1.48 (1.17--1.88)   \<0.01
  Asian (n=5)                               59.6%    1.05 (0.52--2.09)   0.21
  HWE in controls (n=11)                    38.0%    1.40 (1.13--1.74)   \<0.01
  **Heterozygous model (GG vs AG)**                                      
  Overall (n=13)                            0.0%     1.11 (0.92--1.35)   0.25
  Caucasian (n=7)                           0.0%     1.24 (0.98--1.57)   0.06
  Asian (n=5)                               0.0%     0.90 (0.62--1.29)   0.57
  HWE in controls (n=11)                    0.0%     1.15 (0.92--1.42)   0.20

**Notes:** If *I*^2^\<50%, the fixed effects model was used. Otherwise, the random effects model was used.

**Abbreviations:** ERα, estrogen receptor α; OR, crude odds ratio; CI, confidence interval; HWE, Hardy--Weinberg equilibrium.
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